Published 16th November 2017

Mission Therapeutics’ highlights positive Parkinson’s Disease USP30 target and inhibitor Data

Mission Therapeutics, the leading drug discovery and development company focused on selectively targeting deubiquitylating enzymes (DUBs) to treat neurodegenerative diseases, fibrosis, and other diseases with high unmet medical need, is presenting two posters with new research and preclinical data from its USP30 inhibitor Parkinson’s disease programmes at Neuroscience 2017, the 47th Annual Meeting of the Society for Neuroscience, in Washington, DC. The meeting is the world’s largest neuroscience conference.

USP30 is a mitochondrial-associated DUB that has emerged as a promising new target in Parkinson’s disease. It has been implicated in the control of mitophagy, a cellular mitochondrial quality control mechanism. This process regulates the selective clearance of poorly functioning mitochondria by modifying levels of a protein called ubiquitin. Failure of mitochondrial quality control results in the accumulation of dysfunctional mitochondria, which eventually leads to a pathological mechanism that can result in Parkinson’s disease.

Dr Anker Lundemose, Chief Executive Officer of Mission Therapeutics, said:

“DUBs are playing an emerging role as targets across a number of serious diseases, as highlighted in our team’s recently-published Nature Reviews Drug Discovery paper. The data from the studies presented at this conference further enhances our understanding of the cellular mechanisms of USP30 and the significance of inhibiting this particular DUB in Parkinson’s disease. Our research is also providing invaluable information that is helping to shape our preclinical development strategy.”